Adiponectin secretion-promoting compounds have therapeutic potentials in human metabolic diseases. Diallyl biphenyl-type neolignan compounds, magnolol, honokiol, and 4--methylhonokiol, from a extract were screened as adiponectin- secretion promoting compounds in the adipogenic differentiation model of human bone marrow mesenchymal stem cells (hBM-MSCs). In a target identification study, magnolol, honokiol, and 4--methylhonokiol were elucidated as PPARα and PPARγ dual modulators. Diallyl biphenyl-type neolignans affected the transcription of lipid metabolism-associated genes in a different way compared to those of specific PPAR ligands. The diallyl biphenyl-type neolignan structure provides a novel pharmacophore of PPARα/γ dual modulators, which may have unique therapeutic potentials in diverse metabolic diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457167PMC
http://dx.doi.org/10.4062/biomolther.2019.180DOI Listing

Publication Analysis

Top Keywords

diallyl biphenyl-type
16
dual modulators
12
biphenyl-type neolignans
8
pharmacophore pparα/γ
8
pparα/γ dual
8
therapeutic potentials
8
metabolic diseases
8
biphenyl-type neolignan
8
magnolol honokiol
8
honokiol 4--methylhonokiol
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!